

Memoria Producción Científica 2022

- Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, **Sanchez A**, Dakhil S, Camidge DR, Winzer L, Soo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. *J. Clin. Oncol.* 2022. 40. (29):p. 3383-3383. IF:44,544. (1).

- Mateo J, Borque A, Castellano DE, Castro E, Duran M, Font A, **Lorente D**, Mellado B, Rodriguez A, Cuadras M, Planas J, Salas IC, Cordoba S, Gonzalez L, de Falcon MM, Fernandez M, Sampayo M, Malfettone A, Perez R, Carles J. A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naive prostate cancer (mHNPC): ZZFIRST. *J. Clin. Oncol.* 2022. 40. (6):IF:44,544. (1).

- **Lorente D**, Romero N, Lozano R, **Novella SR**, **Montes A**, Mateo J, Castro E, **Sanchez A**, Olmos D. PSA-progression only in high-risk, metastatic hormone-sensitive prostate cancer patients treated with abiraterone in the LATITUDE trial. *J. Clin. Oncol.* 2022. 40. (6):IF:44,544. (1).

- Oria G, Garcia I, Esteban E, Pinto A, **Lorente D**, De Liano AG, Ortega EM, Colomo LJ, Puente J, Gonzalez I, Fernandez O, Anguera G. Atezolizumab (ATZ) with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA): A multicentre, single-arm phase II trial. *Ann. Oncol.* 2022. 33. (7):p. 1333-1333. IF:32,976. (1).

- Isla D, Arriola E, Campelo MRG, Tain PD, Blanco CM, Piqueras MMLB, Vega A, Mateos L, Rodriguez J, Calderon VG, Tarruella MM, **Hernandez AS**, de la Rosa CA, Cabellos RA, Ciriquian JLM, Paul AM, Perez JLF, Mellen AC, Baez L, Paz L. Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Preliminary efficacy results. *Ann. Oncol.* 2022. 33. (7):p. 1247-1248. IF:32,976. (1).

- Arjona A, Cano MT, Gutierrez A, Segura JJ, Perez E, Concepcion V, Sanchez S, Garcia A, Prieto I, Sanchez PB, Torres J, Ramirez M, Prada A, Carrasco J, Artiles M, Villarejo P, Ortega G, **Boldo E**, **Aranda E**, Rufian S. Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (HIPECT4): A randomized phase III study. *Ann. Oncol.* 2022. 33. (7):p. 680-680. IF:32,976. (1).

- Castillon JC,Plana M,Castelo B,Iglesias L,Hernando J,Tur RY,Baste N,Carmona A,Ruiz S,Trigo J,Lorenzo I,Grande E,**Lorente D**,Ugidos L,Marquina G,Garcia A,Taberna M,Villamayor J,Molina J,Alonso T. Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial. Ann. Oncol. 2022. 33. (7):p. 1294-1295. IF:32,976. (1).

- Pascual T,De Las Heras BB,Martinez N,Oliveira M,Simon SP,Lopez RL,Cabrero IR,Alarcon JD,**de Dueñas EM**,Gimenez DM,Cao MG,Sanchez LMM,Murillo SM,de Ceballos HL,Cortes J,Cussac AL,Prat A. PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study. Ann. Oncol. 2022. 33. p. 168-168. IF:32,976. (1).

- de Juan VC,Dols MC,Rodriguez D,Carcereny E,Cantero A,Caro RB,Lopez GB,Castro RL,Sureda BM,del Barco E,Campelo MRG,Guirado M,Herrero CJCC,Granados A,Gonzalez JL,**Hernandez AS**,Ojea CG,Gonzalez M,Vidal O,Pulla MP. Determination of essential biomarkers in lung cancer: A real-world data study in Spain. Ann. Oncol. 2022. 33. p. 50-50. IF:32,976. (1).

- Isla D,Arriola E,Campelo MRG,Marti C,Tain PD,Vega A,Piqueras MLB,Leon L,Calderon VG,Rodriguez J,Majem M,**Sanchez A**,de la Rosa CA,Cabellos RA,Marti JL,Paul AM,Cordero MG,Mellen AC,Baez L,Zugazagoitia J. Phase IIIb study of durvalumab plus platinumemetoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Treatment patterns of chemotherapy combination phase with durvalumab. Ann. Oncol. 2022. 33. p. 98-99. IF:32,976. (1).

- Costa EC,Lorduy AC,Dols MC,Abreu DR,Caro RB,Castro RL,Sureda BM,del Barco E,Guirado M,Bosch J,Gonzalez JL,**Hernandez AS**,Vidal O,Rodriguez J,Martinez JM,Granados A,Padilla A,Bueno MTM,Cantero A,Pulla MP. Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT). Ann. Oncol. 2022. 33. p. 57-57. IF:32,976. (1).

- Massuti B,Nadal E,Camps C,Carcereny E,Cobo M,Domine M,Garcia MR,Gonzalez

JL, Guirado M, Hernando F, Rodriguez D, **Sanchez A**, Sullivan I, Provencio M. Multidisciplinary Thoracic Tumors Board Survey in Spain. *J. Thorac. Oncol.* 2022. 17. (9):p. 107-107. IF:15,609. (1).

- Provencio M, Ortega AL, Coves J, Franco F, Marse R, Domine M, Guirado M, Carcereny E, Fernandez N, **Martinez E**, Blanco R, Leon L, Sanchez JM, Sullivan I, Cobo M, **Sanchez A**, Massuti B. First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study. *J. Thorac. Oncol.* 2022. 17. (9):p. 123-124. IF:15,609. (1).

- Albarran V, Torres J, Auclin E, Esteban J, **Sanchez A**, Benitez G, Garde J, Perez JL, **Soler J**, Areses M, Olmedo E, Insa A, Torres A, Roa D, Dorta M, Cardenas N, Laguna JC, Teixido C, Mezquita L. Spanish Multicenter Retrospective Study of Real-Life Experience of Advanced NSCLC with EGFR Exon 20 Insertions Treated With Amivantamab. *J. Thorac. Oncol.* 2022. 17. (9):p. 474-475. IF:15,609. (1).

- Nadal E, Cantero A, Ortega AL, Domine M, Barba A, Blasco A, Garcia J, Mosquera J, Vazquez S, Rodriguez D, Lopez R, Juan O, **Sanchez A**, Paz L, Hernandez A, Iranzo P, Diz P, Provencio M, Simo M, Navarro V, Bruna J. NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases. *J. Thorac. Oncol.* 2022. 17. (9):p. 350-351. IF:15,609. (1).

- Climent MA, Font A, Duran I, Puente J, Mendez MJ, Saez MI, Lobera CS, Arija J, Gonzalez A, **Sanchez A**, Fita MJ, Esteban E, Alonso T, Gonzalez BM, Maroto P, Lazaro M, Cassinello J, Perez B, Garcias C, Castellano D. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. *Eur. J. Cancer.* 2022. 175. p. 110-119. IF:9,162. (1).

- Valladares M, Garcia P, Luengo JM, Caceres PPP, Trujillo O, Vidal R, Llanos M, Ayala BL, Miron MLL, Salud A, Nogueras LC, Garcia R, Safont MJ, Ferrer EF, Aparicio J, Conesa M, Guillen C, Garcia P, Magan MBM, **Busquier I**, Salgado M, Vila AL, PERSEIDA I. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study. *Cancers.* 2022. 14. (24):6075. IF:6,639. (1).

- Serna R, Sanchez E, de Lope LR, Sanz S, Rodriguez A, Ares D, Cruz A, Franco F, **Sanchez**

A,Campayo MD,Garcia C,Domine M,Blasco A,Sanchez JM,Oramas J,Bosch J,Sala MA,Sereno M,Romero A,Provencio M. Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation. *Cancers*. 2022. 14. (18):4446. IF:6,639. (1).

- Calvo FA,Serrano J,Cambeiro M,Aristu J,Asencio JM,Rubio I,Delgado JM,**Ferrer C**,Desco M,Pascau J. Intra-Operative Electron Radiation Therapy: An Update of the Evidence Collected in 40 Years to Search for Models for Electron-FLASH Studies. *Cancers*. 2022. 14. (15):3693. IF:6,639. (1).

- **Vicent CH,Tudela X**,Ruiz PM,**Pedralva V**,Pastor AJ,**Ahicart D**,**Novella SR**,**Meneu I**,Albuixech AM,**Santamaria MA**,**Fonfria M**,Fuster A,**Anton SO**,**de Dueñas EM**. Machine Learning Models and Multiparametric Magnetic Resonance Imaging for the Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer. *Cancers*. 2022. 14. (14):3508. IF:6,639. (1).

- **Fernandez E**,**Ferrer C**,**Morillo V**,**Rodriguez M**,**Sanchez A**,**Beato I**,**Frances A**,**Muelas R**,**Piquer T**,**Santafe AI**,**Aznar V**,**Ferrer C**. The Impact of Frailty Screening on Radiation Treatment Modification. *Cancers*. 2022. 14. (4):1072. IF:6,639. (1).

- Algara M,Rodriguez E,Martinez FJ,Salinas J,Sanz X,**Beato I**,Manso A,Soler A,Rodriguez JR,Frias A,Calin A,Juan G,Meireles P,Flaquer A,OPTIMAL I. OPTimizing Irradiation through Molecular Assessment of Lymph node (OPTIMAL): a randomized clinical trial. *Radiother. Oncol.* 2022. 176. p. 76-82. IF:6,280. (1).

- **Muelas R**,Garcia R,**Morillo V**,**Bonaque J**,**Sorribes P**,**Garcia F**,**Ferrer C**. The Usefulness of Adaptative Radiotherapy in Prostate Cancer: How, When, and Who?. *Biomedicines*. 2022. 10. (6):1401. IF:6,081. (1).

- Peris J,Peris E,Albiol J,Durgbanshi A,**Ochoa E**,Carda S,Bose D,Esteve J. Liquid chromatography, a valuable tool in the determination of antibiotics in biological, food and environmental samples. *Microchem J.* 2022. 177. 107309. IF:4,821. (1).

- Pena J,Palop A,Masanet MJ,Lacruz M,Plaza R,Hernandez A,**Edo S**,Vallina O. Self-reported cognitive biases in psychosis: Validation of the Davos Assessment of Cognitive Biases Scale (DACOBS) in a Spanish sample of psychotic patients and healthy controls. *J. Psychiatr. Res.* 2022. 155. p. 526-533. IF:4,791. (1)

- **Echeverria I, Peraire M, Penades D, Quintero V, Benito A, Almodovar I, Haro G.** Purpose in Life and Character Strengths as Predictors of Health Sciences Students' Psychopathology During the COVID-19 Pandemic. *Front. Psychiatry.* 2022. 13. 932249. IF:4,157. (2).
- Martin CM, Hernandez R, Cruz P, Fernandez A, **Lorente D**, Lopez H, Ostios L, Antonanzas M, Jimenez P, Garcia T, Calderon C. Dignity and psychosocial related variables in elderly advanced cancer patients. *BMC Geriatr.* 2022. 22. (1):732. IF:3,921. (1).
- O'Higgins M, Rojas LA, **Echeverria I**, Rosello L, Benito A, **Haro G.** Burnout, psychopathology and purpose in life in healthcare workers during COVID-19 pandemic. *Frontiers in Public Health.* 2022. 10. 926328. IF:3,709. (1).
- Guirado M, Martin EF, Villar AF, Martin AN, **Sanchez A.** Clinical impact of delays in the management of lung cancer patients in the last decade: systematic review. *Clin. Transl. Oncol.* 2022. 24. (8):p. 1549-1568. IF:3,405. (3).
- Remon J, Bernabe R, Diz P, Felip E, Gonzalez JL, Lazaro M, Mielgo X, **Sanchez A**, Sullivan I, Massutti B. SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021). *Clin. Transl. Oncol.* 2022. 24. (4):p. 635-645. IF:3,405. (3).
- Benito A, de Fonseca FR, **Haro G.** Sexual Differences in Addictions and Dual Disorders: Importance of Gender Perspective. *Brain Sci.* 2022. 12. (10):1346. IF:3,394. (3).
- Esteve A, **Jovani A**, Benito A, Baquero A, **Haro G**, Rodriguez F. Dual Diagnosis in Adolescents with Problematic Use of Video Games: Beyond Substances. *Brain Sci.* 2022. 12. (8):1110. IF:3,394. (3).
- Castellano F, Benito A, **Jovani A, Fuertes A**, Mari MI, **Haro G.** Sex Differences in Substance Use, Prevalence, Pharmacological Therapy, and Mental Health in Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). *Brain Sci.* 2022. 12. (5):590. IF:3,394. (3).
- Cotaina M, **Peraire M**, Bosca M, **Echeverria I**, Benito A, **Haro G.** Substance Use in the Transgender Population: A Meta-Analysis. *Brain Sci.* 2022. 12. (3):366. IF:3,394. (3)

- **Arnau F**, Benito A, **Villar M**, Ortega ME, Lopez L, **Haro G**. Addressing Dual Disorders in a Medium-Term Admission Unit. *Brain Sci.* 2022. 12. (1):24. IF:3,394. (3).

- Monfort M, Benito A, **Haro G**, **Fuertes A**, Canabate M, Baquero A. The Efficacy of Animal-Assisted Therapy in Patients with Dual Diagnosis: Schizophrenia and Addiction. *Int. J. Environ. Res. Public Health.* 2022. 19. (11):6695. IF:3,390. (1).

- Bivia G, Soldevila P, **Haro G**, Gonzalez V, **Arnau F**, Peyro L, Garcia L, Sanchez MI, Lison JF. The Impact of the COVID-19 Pandemic on the Lifestyles and Levels of Anxiety and Depression of Patients with Schizophrenia: A Retrospective Observational Study. *Healthcare.* 2022. 10. (1):128. IF:2,645. (2).

- Pomar MDB, Sanchez BL, Pla MA, Carrasco AR, Gutierrez LS, Arrieta AY, **Carreras PS**, Medina SG, Soria JBM, Miranda MB, Martinez MSL, Suau OT, Usieto M, Gonzalez FV, Osinaga JA, Echevarria EM, Garcia K. A real-life study of the medium to long-term effectiveness of a hypercaloric, hyperproteic enteral nutrition formula specifically for patients with diabetes on biochemical parameters of metabolic control and nutritional status. *Endocrinol. Diabetes Nutr.* 2022. 69. (5):p. 331-337. IF:1,417. (4).

- Bonet LGG, Piqueras C, Rosello E, Broseta R, **de las Penas R**. Long-term survival of glioblastoma: A systematic analysis of literature about a case. *Neurocirugia.* 2022. 33. (5):p. 227-236. IF:0,553. (4).

- **Sanchez AL**, **Morillo V**, **Santafe A**, **Ferrer C**. Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience. *Radiation Oncology Journal.* 2022. 40. (3):p. 192-199.